secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001326190-24-000046
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune names Greg Weaver CFO, with $475k salary and 225k option grant
------------------------------------------------------------------------

- Mr. Weaver appointed CFO effective Nov 11, 2024; previously CFO at atai Life Sciences.
- Employment terms: annual salary $475k, target bonus 40%, sign-on option for 225k shares and 75k RSUs.
- Andrew Shutterly transitions from Interim CFO to Corporate Controller.
- Weaver led $225M IPO at atai Life Sciences and has 25+ years of biotech finance experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000132619024000046/0001326190-24-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000132619024000046/alt-20241111x8k.htm
  HTML page:      https://secwatch.observer/filing/0001326190-24-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer